Moderna, Inc. (NASDAQ:MRNA) President Sells $1,575,300.00 in Stock

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 15,000 shares of Moderna stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $105.02, for a total value of $1,575,300.00. Following the transaction, the president now directly owns 1,486,241 shares in the company, valued at $156,085,029.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Stephen Hoge also recently made the following trade(s):

• On Thursday, February 29th, Stephen Hoge sold 2,388 shares of Moderna stock. The stock was sold at an average price of $94.57, for a total transaction of $225,833.16.

Moderna Stock Down 0.6 %

MRNA stock opened at $101.41 on Friday. The company has a 50 day moving average of $100.63 and a two-hundred day moving average of $93.64. The company has a market cap of $38.83 billion, a price-to-earnings ratio of -8.17 and a beta of 1.62. Moderna, Inc. has a 12-month low of $62.55 and a 12-month high of $144.43. The company has a quick ratio of 3.36, a current ratio of 3.42 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $1.33. The business had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.53 billion. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. Moderna’s revenue for the quarter was down 44.9% compared to the same quarter last year. During the same period in the prior year, the business posted $3.61 earnings per share. On average, equities analysts anticipate that Moderna, Inc. will post -7.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Royal Bank of Canada restated an “outperform” rating and set a $125.00 target price on shares of Moderna in a report on Thursday, March 28th. Canaccord Genuity Group raised their price objective on Moderna from $82.00 to $91.00 and gave the stock a “hold” rating in a research note on Friday, February 23rd. Oppenheimer raised Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 target price on the stock in a research report on Tuesday, January 2nd. Jefferies Financial Group reiterated a “buy” rating and issued a $125.00 price target on shares of Moderna in a research report on Tuesday, April 9th. Finally, William Blair reissued a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Moderna presently has an average rating of “Hold” and an average target price of $126.49.

Institutional Investors Weigh In On Moderna

Several institutional investors have recently made changes to their positions in MRNA. ICA Group Wealth Management LLC bought a new position in Moderna during the fourth quarter valued at approximately $27,000. First Pacific Financial acquired a new position in shares of Moderna during the 3rd quarter worth $27,000. Ogorek Anthony Joseph NY ADV bought a new position in shares of Moderna during the 4th quarter valued at $27,000. Stonebridge Capital Advisors LLC raised its holdings in shares of Moderna by 79.1% during the 1st quarter. Stonebridge Capital Advisors LLC now owns 283 shares of the company’s stock valued at $49,000 after purchasing an additional 125 shares in the last quarter. Finally, Arlington Trust Co LLC lifted its stake in shares of Moderna by 4,833.3% in the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after purchasing an additional 290 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.